-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
SP-471P
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/sp-471p.gif)
| Category | Virus Protease |
| Description | SP-471P is a potent dengue virus (DENV) protease inhibitor with EC50s of 5.9 μM, 1.4 μM, 5.1 μM and 1.7 μM for DENV1, DENV2, DENV3 and DENV4, respectively and CC50 value over 100 μM. SP-471P can reduce DENV viral RNA synthesis. |
Product Information
| Synonyms | CHEMBL4854249|SP-471P|BDBM50578685|HY-144645|CS-0433376 |
| Molecular Weight | 604.5 |
| Molecular Formula | C33H26BrN5O2 |
| Canonical SMILES | C1=CC(=CC(=C1)Br)CN2C3=C(C=C(C=C3)C4=CC(=CC=C4)C(=NO)N)C5=C2C=CC(=C5)C6=CC(=CC=C6)C(=NO)N |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 885 |
| Exact Mass | 603.12699 |
| In Vitro | SP-471P (0-10 μM) shows low micromolar efficacy for DENV1, DENV2, DENV3 and DENV4 with EC50s of 5.9 μM, 1.4 μM, 5.1 μM and 1.7 μM, respectively. SP-471P (10 μM; 48 hours) exhibits an EC50 value of 1.5 μM for ADE infection in human peripheral blood mononuclear cells. SP-471P (10 μM; 6-54 hours) reduces viral RNA synthesis of DENV2. SP-471P (10 μM; 30 hours) targets the NS3int cleavage site of DENV in DENV2-infected Huh7 cells. |
| Target | EC50: 5.9 μM (DENV1), 1.4 μM (DENV2), 5.1 μM (DENV3), 1.7 μM (DENV4) |
| XLogP3-AA | 7.1 |
